

# Nasogastric and intravenous erythromycin as prokinetic in intensive care patients: a randomised controlled study

<b>Submission date</b> 12/09/2003	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 12/09/2003	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 31/03/2020	<b>Condition category</b> Signs and Symptoms	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr A Guha

### Contact details

Anaesthesia  
University Hospital Aintree  
Longmoor Lane  
Fazakerley  
Liverpool  
United Kingdom  
L9 7AL  
+44 (0)151 529 5152 / 5153  
abc@email.com

## Additional identifiers

### Protocol serial number

N0025107242

## Study information

**Scientific Title**

Nasogastric and intravenous erythromycin as prokinetic in intensive care patients: a randomised controlled study

**Study objectives**

Erythromycin's effect on gastric emptying in intensive care

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Signs and Symptoms: Gastric emptying

**Interventions**

A 5 ml sample of blood will be taken for measuring baseline paracetamol content. 1.5 g of soluble paracetamol will be administered to them through their nasogastric tube. They will then be randomised to receive 250 g of either nasogastric or intravenous erythromycin. Further blood samples (5 ml each time) will be taken at 15, 30, 45, 60, 120, 180 and 240 min after giving paracetamol. These samples will then be sent to the laboratory for assay. After obtaining the data, these will be analysed for statistical significance.

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Erythromycin

**Primary outcome(s)**

Not provided at time of registration

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

01/07/2003

# Eligibility

## Key inclusion criteria

Intensive Care patients who will be recruited into the study if they exhibit a failure to absorb nasogastric feed.

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Not Specified

## Sex

Not Specified

## Key exclusion criteria

Not provided at time of registration

## Date of first enrolment

01/01/2002

## Date of final enrolment

01/07/2003

# Locations

## Countries of recruitment

United Kingdom

England

## Study participating centre

University Hospital Aintree

Liverpool

United Kingdom

L9 7AL

# Sponsor information

## Organisation

Department of Health (UK)

# Funder(s)

## Funder type

Hospital/treatment centre

## Funder Name

Aintree Hospitals NHS Trust (UK)

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration